336 related articles for article (PubMed ID: 23535814)
21. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
22. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.
Montalto G; Tripi S; Cartabellotta A; Fulco M; Soresi M; Di Gaetano G; Carroccio A; Levrero M
Am J Gastroenterol; 1998 Jun; 93(6):950-3. PubMed ID: 9647026
[TBL] [Abstract][Full Text] [Related]
23. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
[TBL] [Abstract][Full Text] [Related]
24. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls.
Castelruiz Y; Larrea E; Boya P; Civeira MP; Prieto J
Hepatology; 1999 Jun; 29(6):1900-4. PubMed ID: 10347136
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
27. Interferon-ribavirin-associated ischemic colitis.
Punnam SR; Pothula VR; Gourineni N; Punnam A; Ranganathan V
J Clin Gastroenterol; 2008 Mar; 42(3):323-5. PubMed ID: 18223489
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.
Markowitz JS; Gutterman EM; Hodes D; Klaskala W
J Viral Hepat; 2005 Mar; 12(2):176-85. PubMed ID: 15720533
[TBL] [Abstract][Full Text] [Related]
29. Interferon beta for multiple sclerosis.
Connelly JF
Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
32. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with interferon alpha and beta to chronic hepatitis C.
Horiike N; Hino H; Tanaka Y; Miyaoka H; Miki S; Yamashita S; Matsuura B; Kubo Y; Ikeda Y; Akbar SM; Masumoto T; Michitaka K; Onji M
Oncol Rep; 2003; 10(1):157-61. PubMed ID: 12469163
[TBL] [Abstract][Full Text] [Related]
34. Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS.
Nguyen TQ; Lewis JH
Drug Saf; 2014 Feb; 37(2):109-21. PubMed ID: 24442762
[TBL] [Abstract][Full Text] [Related]
35. Concurrent administration of interferon alfa-2b and beta-1a.
Tanvetyanon T; Stadtmauer EA; Kerson LA
Ann Pharmacother; 2003 Jan; 37(1):77-9. PubMed ID: 12503938
[TBL] [Abstract][Full Text] [Related]
36. [Interferon therapy for acute hepatitis C; changes in serum markers associated with HCV and clinical effects].
Fukui S; Tohyama H; Iwabuchi S
Nihon Rinsho; 1994 Jul; 52(7):1847-51. PubMed ID: 7521429
[TBL] [Abstract][Full Text] [Related]
37. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
[TBL] [Abstract][Full Text] [Related]
38. Psychiatric side effects of interferon treatment.
Patten SB
Curr Drug Saf; 2006 May; 1(2):143-50. PubMed ID: 18690925
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic alpha-interferons protein: structure, production, and biosimilar.
El-Baky NA; Redwan EM
Prep Biochem Biotechnol; 2015; 45(2):109-27. PubMed ID: 24785737
[TBL] [Abstract][Full Text] [Related]
40. [Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy].
Samson M; Audia S; Duchêne C; Perinet I; Bielefeld P; Besancenot JF
Rev Med Interne; 2009 Sep; 30(9):816-9. PubMed ID: 19201069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
